This website is intended only for healthcare professionals outside the UK and Australia.
All our specialties
Congresses
Stay up to date with the latest scientific information from international medical congresses.
Diseases
Explore disease information across relevant specialties
All our specialties
External site
By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.
Srikala Sridhar comments on the interim analysis of the NORSE study of first-line erdafitinib plus cetrelimab in cisplatin-ineligible patients with advanced urothelial carcinoma and fibroblast growth factor receptor alterations.
This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.